Bleiberg H
Institut Jules Bordet, Brussels, Belgium.
Br J Cancer. 1998 Jun;77 Suppl 4(Suppl 4):1-3. doi: 10.1038/bjc.1998.427.
Oxaliplatin (trans-/-diaminocyclohexane oxalatoplatinum; L-OHP) is a new platinum derivative for the treatment of advanced colorectal cancer. Preclinical data have shown that oxaliplatin is active in a wide range of human and murine tumour cell lines, and has been found to be non-cross-resistant with cisplatin in various cisplatin-resistant cell lines and tumours. Oxaliplatin in combination with 5-fluorouracil (5-FU) leads to synergistic antiproliferative activity both in vivo and in vitro. Clinical data have shown that oxaliplatin is active and well tolerated both as monotherapy and in combination with 5-FU/folinic acid in first- or second-line treatment of patients with metastatic colorectal cancer. Oxaliplatin has a very good safety profile, and studies have confirmed that peripheral sensory neuropathy is related to the cumulative dose of oxaliplatin administered and that this neuropathy is generally reversible after discontinuation of treatment. High response rates and prolonged survival have been achieved in metastatic colorectal cancer patients, even after 5-FU failure.
奥沙利铂（反式-/-二氨基环己烷草酸铂；L-OHP）是一种用于治疗晚期结直肠癌的新型铂类衍生物。临床前数据表明，奥沙利铂在多种人类和小鼠肿瘤细胞系中具有活性，并且在各种顺铂耐药细胞系和肿瘤中发现它与顺铂无交叉耐药性。奥沙利铂与5-氟尿嘧啶（5-FU）联合使用在体内和体外均产生协同抗增殖活性。临床数据表明，奥沙利铂在转移性结直肠癌患者的一线或二线治疗中作为单药治疗或与5-FU/亚叶酸联合使用时均具有活性且耐受性良好。奥沙利铂具有非常好的安全性，研究证实外周感觉神经病变与奥沙利铂的累积给药剂量有关，并且这种神经病变在停药后通常是可逆的。即使在5-FU治疗失败后，转移性结直肠癌患者也实现了高缓解率和延长生存期。
